ArQule is pursuing a drug research major in molecular biology, with a focus on cancer cell termination. The biotechnology firm works independently and with other drugmakers to discover new potential drug compounds based on its cancer-inhibiting technology platform. ArQule is developing a portfolio of oncology drugs, with a handful of anti-cancer compounds undergoing clinical trials. It is testing its most advanced candidate, ARQ 197, as a treatment for a variety of tumor types such as non-small cell lung cancer and colorectal cancer through a partnership with Daiichi Sankyo.